TRANS GENIC GROUP INC. Logo

TRANS GENIC GROUP INC.

Biotech firm offering drug discovery support and investment/consulting services.

2342 | T

Overview

Corporate Details

ISIN(s):
JP3635720000
LEI:
Country:
Japan
Address:
福岡市中央区天神二丁目3番36号

Description

TRANS GENIC GROUP INC. is a biotechnology company that operates through two main business segments: Drug Discovery Support and Investment & Consulting. The Drug Discovery Support division provides comprehensive services across the entire drug development pipeline, from basic research to non-clinical and clinical trials. Core services include the contract production of genetically modified animals, particularly mice, using genome editing technologies like CRISPR/Cas9. The company also specializes in contract antibody production, glycosylation analysis, and the supply of model mice. The Investment & Consulting segment focuses on M&A, business succession, and providing advisory and support services for business revitalization.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 02:36
確認書
Japanese 8.2 KB
2025-11-13 02:33
半期報告書-第28期(2025/04/01-2026/03/31)
Japanese 189.2 KB
2025-08-01 09:45
訂正確認書
Japanese 8.2 KB
2025-08-01 09:44
訂正有価証券報告書-第27期(2024/04/01-2025/03/31)
Japanese 667.3 KB
2025-07-02 05:53
訂正臨時報告書
Japanese 24.4 KB
2025-07-01 10:02
臨時報告書
Japanese 24.4 KB
2025-06-30 09:38
確認書
Japanese 8.6 KB
2025-06-30 09:37
内部統制報告書-第27期(2024/04/01-2025/03/31)
Japanese 23.7 KB
2025-06-30 09:34
有価証券報告書-第27期(2024/04/01-2025/03/31)
Japanese 1.1 MB
2025-06-13 10:13
臨時報告書
Japanese 21.2 KB
2025-04-23 09:55
臨時報告書
Japanese 20.1 KB
2024-11-13 02:42
確認書
Japanese 8.5 KB
2024-11-13 02:41
半期報告書-第27期(2024/04/01-2025/03/31)
Japanese 191.9 KB
2024-06-24 08:30
臨時報告書
Japanese 19.8 KB
2024-06-21 07:03
有価証券報告書-第26期(2023/04/01-2024/03/31)
Japanese 1.0 MB

Automate Your Workflow. Get a real-time feed of all TRANS GENIC GROUP INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TRANS GENIC GROUP INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TRANS GENIC GROUP INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CAMBRIDGE COGNITION HOLDINGS PLC Logo
Develops digital solutions and a platform for CNS clinical trials to assess brain health.
United Kingdom
COG
A clinical-stage biopharmaceutical company developing novel cancer therapeutics.
Japan
4575
Captor Therapeutics S.A. Logo
Develops Targeted Protein Degradation therapies for cancer and autoimmune diseases.
Poland
CTX
Cardiff Oncology, Inc. Logo
A clinical-stage biotech developing cancer therapies that inhibit Polo-like kinase 1.
United States of America
CRDF
Cardio Diagnostics Holdings, Inc. Logo
Develops AI-powered epigenetic and genetic tests for early heart disease detection.
United States of America
CDIO
CASSAVA SCIENCES INC Logo
Clinical-stage biotech developing treatments for Central Nervous System disorders.
United States of America
SAVA
Celcuity Inc. Logo
Clinical-stage biotech developing targeted therapies for multiple solid tumors.
United States of America
CELC
Develops and manufactures cellulose-based nonwoven fabrics for the cosmetics sector.
South Korea
318160
CEL SCI CORP Logo
Clinical-stage biotech developing immunotherapies for cancer and infectious diseases.
United States of America
CVM
Celyad Oncology SA Logo
Biotechnology company developing innovative CAR-T cell therapies to treat cancer.
Belgium
CYAD

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.